Skip to main content
. 2023 Mar 9;61(3):2201193. doi: 10.1183/13993003.01193-2022

FIGURE 1.

FIGURE 1

Study design. The efficacy end-points were evaluated on days 42 and 84. #: efficacy interim analysis planned in the middle of Cohort 2 (∼15 subjects enrolled) with the potential to adjust the dose for an additional ∼18 subjects; : 7 h post-challenge. PK: pharmacokinetics; EOT: end of treatment; ED: early discontinuation; EOS: end of study; FENO: fractional exhaled nitric oxide.